Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - BIO-PATH HOLDINGS INC | v242926_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 13, 2011
BIO-PATH HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
|
Utah
|
000-53404
|
87-0652870
|
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
2626 South Loop, Suite 180, Houston, Texas
|
77054
|
|
(Address of principal executive offices)
|
(Zip Code)
|
801-580-2326
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On December 13, 2011, Bio-Path Holdings, Inc. (the “Company”) issued a press release titled “Bio-Path Holdings’ Initial Phase I Data in Leukemia Clinical Trial Demonstrates that Its Neutral Lipid Delivery Technology Antisense Drug BP-100-1.01 (Liposomal Grb-2) Is Well Tolerated with Activity Seen at Low-Starting Dose.”
A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit
|
||
|
Number
|
Description
|
|
|
99.1
|
|
Press Release dated December 13, 2011
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIO-PATH HOLDINGS, INC.
|
||
|
Dated: December 13, 2011
|
By:
|
/s/ Peter H. Nielsen
|
|
Peter H. Nielsen
|
||
|
President and Chief Executive Officer
|
||
EXHIBIT INDEX
|
Exhibit
|
||
|
Number
|
Description
|
|
|
99.1
|
|
Press Release dated December 13, 2011
|